Emma K. Accorsi

2.3k total citations · 3 hit papers
19 papers, 1.1k citations indexed

About

Emma K. Accorsi is a scholar working on Infectious Diseases, Epidemiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Emma K. Accorsi has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 6 papers in Epidemiology and 3 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Emma K. Accorsi's work include SARS-CoV-2 and COVID-19 Research (9 papers), SARS-CoV-2 detection and testing (5 papers) and Viral gastroenteritis research and epidemiology (3 papers). Emma K. Accorsi is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (9 papers), SARS-CoV-2 detection and testing (5 papers) and Viral gastroenteritis research and epidemiology (3 papers). Emma K. Accorsi collaborates with scholars based in United States, Switzerland and Israel. Emma K. Accorsi's co-authors include Amadea Britton, Nong Shang, Katherine E. Fleming-Dutra, Jennifer R. Verani, Gordana Derado, Zachary Smith, Stephanie J. Schrag, Joseph D. Miller, Liane Guild and J. L. Torres-Pérez and has published in prestigious journals such as JAMA, PLoS ONE and American Journal of Clinical Nutrition.

In The Last Decade

Emma K. Accorsi

19 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

2022 403 citations Emma K. Accorsi, Amadea Britton et al. JAMA profile →
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023

2023 76 citations Ruth Link‐Gelles, Allison Avrich Ciesla et al. MMWR Morbidity and Mortality Weekly Report profile →
Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024

2025 26 citations Miwako Kobayashi, Andrew J. Leidner et al. MMWR Morbidity and Mortality Weekly Report profile →

Peers

Countries citing papers authored by Emma K. Accorsi

Since Specialization

Citations

This map shows the geographic impact of Emma K. Accorsi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma K. Accorsi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma K. Accorsi more than expected).

Fields of papers citing papers by Emma K. Accorsi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma K. Accorsi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma K. Accorsi. The network helps show where Emma K. Accorsi may publish in the future.

Co-authorship network of co-authors of Emma K. Accorsi

This figure shows the co-authorship network connecting the top 25 collaborators of Emma K. Accorsi. A scholar is included among the top collaborators of Emma K. Accorsi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma K. Accorsi. Emma K. Accorsi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 breakdown → 2025 ·MMWR Morbidity and Mortality Weekly Report ·Miwako Kobayashi, Andrew J. Leidner, Ryan Gierke, (unknown), Emma K. Accorsi, Pedro L. Moro, Mini Kamboj, George A. Kuchel, Robert Schechter, Jamie Loehr, Adam L. Cohen	26
2	Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023 2023 ·MMWR Morbidity and Mortality Weekly Report ·Katherine E. Fleming-Dutra, Allison Avrich Ciesla, Lauren E. Roper, Zachary Smith, Joseph D. Miller, Emma K. Accorsi, Jennifer R. Verani, Nong Shang, Gordana Derado, Ryan E. Wiegand, Tamara Pilishvili, Amadea Britton, Ruth Link‐Gelles	11
3	Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods 2023 ·Open Forum Infectious Diseases ·Allison Avrich Ciesla, Ryan E. Wiegand, Zachary Smith, Amadea Britton, Katherine E. Fleming-Dutra, Joseph H. Miller, Emma K. Accorsi, Jennifer R. Verani, Nong Shang, Gordana Derado, Tamara Pilishvili, Ruth Link‐Gelles	7
4	Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023 breakdown → 2023 ·MMWR Morbidity and Mortality Weekly Report ·Ruth Link‐Gelles, Allison Avrich Ciesla, Lauren E. Roper, Heather M. Scobie, Akilah R. Ali, Joseph D. Miller, Ryan E. Wiegand, Emma K. Accorsi, Jennifer R. Verani, Nong Shang, Gordana Derado, Amadea Britton, Zachary Smith, Katherine E. Fleming-Dutra	76
5	Notes from the Field: Update on Pediatric Intracranial Infections — 19 States and the District of Columbia, January 2016–March 2023 2023 ·MMWR Morbidity and Mortality Weekly Report ·Emma K. Accorsi, Matt Hall, Adam L. Hersh, Samir S. Shah, Stephanie J. Schrag, Adam L. Cohen	4
6	Post-COVID conditions and healthcare utilization among adults with and without disabilities—2021 Porter Novelli FallStyles survey 2022 ·Disability and health journal ·Maureen J. Miller, Leora R. Feldstein, (unknown), Ian D. Plumb, Emma K. Accorsi, Qing C. Zhang, Qi Cheng, Jean Y. Ko, Valentine Wanga, (unknown), (unknown), Jeanne Bertolli, Sharon Saydah	5
7	Long-term diet and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and Coronavirus Disease 2019 (COVID-19) severity 2022 ·American Journal of Clinical Nutrition ·Yiyang Yue, Wenjie Ma, Emma K. Accorsi, Ming Ding, Frank B. Hu, Walter C. Willett, (unknown), Qi Sun, (unknown), Stephanie A. Smith‐Warner, Shilpa N Bhupathiraju	16
8	Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance 2022 ·JAMA ·Amadea Britton, Katherine E. Fleming-Dutra, Nong Shang, Zachary Smith, Tandin Dorji, Gordana Derado, Emma K. Accorsi, Umed A. Ajani, Joseph D. Miller, Stephanie J. Schrag, Jennifer R. Verani	59
9	Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants breakdown → 2022 ·JAMA ·Emma K. Accorsi, Amadea Britton, Katherine E. Fleming-Dutra, Zachary Smith, Nong Shang, Gordana Derado, Joseph D. Miller, Stephanie J. Schrag, Jennifer R. Verani	403
10	Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 2022 ·MMWR Morbidity and Mortality Weekly Report ·Ruth Link‐Gelles, Allison Avrich Ciesla, Katherine E. Fleming-Dutra, Zachary Smith, Amadea Britton, Ryan E. Wiegand, Joseph D. Miller, Emma K. Accorsi, Stephanie J. Schrag, Jennifer R. Verani, Nong Shang, Gordana Derado, Tamara Pilishvili	88
11	Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance 2022 ·JAMA ·Katherine E. Fleming-Dutra, Amadea Britton, Nong Shang, Gordana Derado, Ruth Link‐Gelles, Emma K. Accorsi, Zachary Smith, Joseph D. Miller, Jennifer R. Verani, Stephanie J. Schrag	88
12	Pediatric Brain Abscesses, Epidural Empyemas, and Subdural Empyemas Associated with Streptococcus Species — United States, January 2016–August 2022 2022 ·MMWR Morbidity and Mortality Weekly Report ·Emma K. Accorsi, Sopio Chochua, Heidi L. Moline, Matt Hall, Adam L. Hersh, Samir S. Shah, Amadea Britton, Paulina A. Hawkins, Wei Xing, (unknown), (unknown), Lesley McGee, Stephanie J. Schrag, Adam L. Cohen	21
13	How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19 2021 ·European Journal of Epidemiology ·Emma K. Accorsi, Xueting Qiu, (unknown), Lee Kennedy‐Shaffer, Rebecca Kahn, Keya Joshi, Edward Goldstein, Mats Julius Stensrud, René Niehus, Müge Çevik, Marc Lipsitch	73
14	Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States 2021 ·PLoS ONE ·(unknown), Thao Nguyen, (unknown), (unknown), (unknown), Yiling Liu, Emma K. Accorsi, Steven J. Skates, John P. Santa Maria, (unknown), Mark Kalinich	11
15	Whole microbial community viability is not quantitatively reflected by propidium monoazide sequencing approach 2021 ·Microbiome ·Ya Wang, Yan Yan, Kelsey N. Thompson, Sena Bae, Emma K. Accorsi, Yancong Zhang, Jiaxian Shen, Hera Vlamakis, Erica M. Hartmann, Curtis Huttenhower	52
16	Determinants of Staphylococcus aureus carriage in the developing infant nasal microbiome 2020 ·Genome biology ·Emma K. Accorsi, Eric A. Franzosa, Tiffany Hsu, Regina Joice Cordy, Ayala Maayan‐Metzger, Hanaa Jaber, (unknown), (unknown), Casey DuLong, Marc Lipsitch, Gili Regev‐Yochay, Curtis Huttenhower	16
17	Sleeping Within Six Feet: Challenging Oregon’s Labor Housing COVID-19 Guidelines 2020 ·Journal of Agromedicine ·Emma K. Accorsi, (unknown), Linda McCauley, (unknown)	8
18	Application of hyperspectral remote sensing to cyanobacterial blooms in inland waters 2015 ·Remote Sensing of Environment ·Raphael M. Kudela, Sherry L. Palacios, David Austerberry, Emma K. Accorsi, Liane Guild, J. L. Torres-Pérez	154
19	Extraordinary Natural Ability: Anagram Solution as an Extension of Normal Reading Ability 2009 ·eScholarship (California Digital Library) ·Emma K. Accorsi, (unknown), (unknown), Whitney Tabor	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact